Lisata Therapeutics Agrees to Kuva Labs Buyout at $4 Per Share
Lisata Therapeutics has announced an agreement to be acquired by Kuva Labs. The terms of the deal indicate a purchase price of $4 per share for Lisata Therapeutics. This transaction represents a significant corporate development for both entities involved.
Lisata Therapeutics has entered into a definitive agreement for its acquisition by Kuva Labs. Under the terms of the agreement, Kuva Labs will purchase Lisata Therapeutics at a price of $4 per share.
This corporate transaction signifies a notable event for both companies. Further details regarding the financial implications or strategic rationale behind the buyout were not immediately available.
According to Yahoo Finance, Lisata Therapeutics has agreed to the Kuva Labs buyout at $4 per share.



